Pharsight

Drugs that contain Fidaxomicin

1. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(10 months ago)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(3 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jan, 2024

(4 months ago)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(2 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(3 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jan, 2028

(3 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(10 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-367) Jan 24, 2027
New Patient Population(NPP) Jan 24, 2023
Pediatric Exclusivity(PED) Jul 24, 2023
New Chemical Entity Exclusivity(NCE) May 27, 2016

NCE-1 date: 24 July, 2022

Market Authorisation Date: 27 May, 2011

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents